Logo image
Back
Antisense oligonucleotide: A potential therapeutic intervention for chronic kidney disease
Journal article   Open access   Peer reviewed

Antisense oligonucleotide: A potential therapeutic intervention for chronic kidney disease

Y. Li, Y. Tan, R. Zhang, T. Wang, N. Na, T. Zheng, R.N. Veedu and S. Chen
Kidney and Dialysis, Vol.2(1), pp.16-37
2022
DOI: https://doi.org/10.3390/kidneydial2010004
pdf
Antisense oligonucleotide - A potential therapeutic intervention for chronic kidney disease.pdfDownloadView
Published (Version of Record)CC BY V4.0,  Open Access
pdf
kidneydial.pdfDownloadView
Supplementary Information Open Access
url
Free to Read *No subscription requiredView

Abstract

Chronic kidney disease (CKD) is a global public health issue that places an increasing burden on the healthcare systems of both the developed and developing countries. CKD is a progressive and irreversible condition, affecting approximately 10% of the population worldwide. Patients that have progressed to end-stage renal disease (ESRD) require expensive renal replacement therapy, i.e., dialysis or kidney transplantation. Current CKD therapy largely relies on the use of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs). However, these treatments by no means halt the progression of CKD to ESRD. Therefore, the development of new therapies is urgently needed. Antisense oligonucleotide (ASO) has recently attracted considerable interest as a drug development platform. Thus far, eight ASO-based drugs have been granted approval by the US Food and Drug Administration for the treatment of various diseases. Herein, we review the ASOs developed for the identification of CKD-relevant genes and/or the simultaneous development of the ASOs as potential therapeutics towards treating CKD.

Details

Metrics

275 File views/ downloads
155 Record Views
Logo image